Evidence map›Paper›PMID 26830878›Full record

ArticleCell2016

Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

Leonardo Morsut, Kole T Roybal, Xin Xiong, Russell M Gordley, Scott M Coyle, Matthew Thomson, Wendell A Lim

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 571 papers.

0numbers the graph read from it
0cells of the map it votes in
571citing papers in PubMed
38.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

571 citing papers in PubMed, 999 citations in OpenAlex.

  1. Review
  2. Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026
    Review
  3. Article
  4. Article
  5. Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  10. Article
  11. Article
  12. Membrane-Associated Biomolecules for Synthetic Cell Signalling.Chembiochem : a European journal of chemical biology · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Programming T cells for intercellular genome editing.bioRxiv : the preprint server for biology · 2026
    Article
  18. Article
  19. Review
  20. Article

511 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Leonardo MorsutDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute.
Kole T RoybalDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute.
Xin XiongDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute.
Russell M GordleyDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute.
Scott M CoyleDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute.
Matthew ThomsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA.
Wendell A LimDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Center for Systems and Synthetic Biology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute. Electronic address: wendell.lim@ucsf.edu.
Howard Hughes Medical Institute · USUniversity of California, San Francisco · US

Funding

Rewiring Therapeutic Cells: User-Controlled T Cells and Stem CellsP50GM081879 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2010 to 2017
$19.0M
Cellular Control:Synthetic Signaling/Motility (RMI)PN2EY016546 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2005 to 2014
$16.0M
PROTEIN RECOGNITION IN SIGNAL TRANSDUCTIONR01GM055040 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 1997 to 2015
$3.5M
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic CellsR01CA196277 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2014 to 2018
$3.3M
Quantitative models for controlling collective cell fate selection in stem cellsDP5OD012194 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMSON, MATTHEW W. · 2012 to 2016
$1.8M
Engineering Synthetic Receptor Systems That Can Detect Specific Cell-Cell Contact SignalsK99EB021030 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORSUT, LEONARDO · 2015 to 2016
$195k
Engineering Synthetic Cell Motility Systems (RMI)PN1EY016546 · NEI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LIM, WENDELL A · 2004 to 2004
$76k
Howard Hughes Medical InstituteNCI NIH HHS R01 CA196277NEI NIH HHS PN2 EY016546NIBIB NIH HHS 1K99EB021030NIBIB NIH HHS K99 EB021030NIGMS NIH HHS P50 GM081879NIGMS NIH HHS P50GM081879NIGMS NIH HHS R01 GM055040NIH HHS DP5 OD012194
6 · The paper itself

Abstract

The Notch protein is one of the most mechanistically direct transmembrane receptors-the intracellular domain contains a transcriptional regulator that is released from the membrane when engagement of the cognate extracellular ligand induces intramembrane proteolysis. We find that chimeric forms of Notch, in which both the extracellular sensor module and the intracellular transcriptional module are replaced with heterologous protein domains, can serve as a general platform for generating novel cell-cell contact signaling pathways. Synthetic Notch (synNotch) pathways can drive user-defined functional responses in diverse mammalian cell types. Because individual synNotch pathways do not share common signaling intermediates, the pathways are functionally orthogonal. Thus, multiple synNotch receptors can be used in the same cell to achieve combinatorial integration of environmental cues, including Boolean response programs, multi-cellular signaling cascades, and self-organized cellular patterns. SynNotch receptors provide extraordinary flexibility in engineering cells with customized sensing/response behaviors to user-specified extracellular cues.

Indexed as

Cell EngineeringSignal TransductionAnimalsCell LineDogsHumansMiceNeuronsReceptors, NotchSynthetic BiologyTranscription, GeneticReceptors, Notch

Identifiers

PMID26830878
PMCPMC4752866
OpenAlexW2256857837

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.